Current Pharmaceutical Analysis (CPA), a scholarly journal focused on advances in pharmaceutical and biomedical analysis, is pleased to announce that its 2025 real-time CiteScore has advanced to 2.4. This progress demonstrates the journal's expanding role in disseminating high-quality research across the pharmaceutical sciences.
With a 2024 Impact Factor of 1.5 - doubling from the previous year - CPA shows strong growth potential and increasing influence in the field. The journal is indexed in major databases including SCIE, Scopus, ProQuest, and EMBASE, ensuring broad accessibility for researchers worldwide.
CPA covers essential areas of pharmaceutical research, from drug discovery and development to toxicology, pharmaceutics, and pharmaceutical biotechnology. The journal serves as an important platform for sharing innovations that bridge laboratory research with clinical applications.
This advancement in CiteScore reflects CPA's commitment to quality and its growing contribution to the global pharmaceutical research community. The journal looks forward to continuing its progress and supporting important scientific developments in the years to come.